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Abstract 
This study examined the variables related to psychotropic medication use among 73 
adults with intellectual disabilities living in community residential settings in Ontario, Canada 
over a one-year period based on staff reports. Despite only 16% percent having a documented 
psychiatric diagnosis, 84% of these individuals were receiving psychotropic medications, and 
74% were receiving two or more psychotropic medications (polypharmacy). Anti-psychotics, 
anti-anxiety medications, and anti-convulsant medications were the most frequently reported 
drug classes. While problem behaviour was reported for 60% of the participants, only 33% had a 
formal behaviour plan. There was a significant relationship between the reported number of 
problem behaviours and the reported number of prescribed psychotropic medications. Reported 
medication reviews did not adhere to the Canadian 'Consensus Guidelines for the Primary Care 
of Adults with Developmental Disabilities' (Sullivan et aI., 2006). Results, based on staff 
reports, suggested incongruence with recommended best practices, and raised concern about 
over-reliance on psychotropic medication with these individuals. 
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Psychotropic Medication Use in Adults with Intellectual Disabilities 
Living in Community Settings 
Individuals with intellectual disabilities (ID) are at an increased risk to develop mental 
health issues and/or behavioural problems across the lifespan (Sturmey, Lindsay, Didden, 2007). 
Intellectual disability is the current term used to describe the same group of individuals who have 
been previously referred to as having a 'developmental disability' or 'mental retardation' 
(AAIDD, 2011). Compared to the general population, the prevalence of psychiatric disorders in 
individuals with intellectual disabilities is approximately 2-4 times greater (Borthwick-Duffy, 
1994; DM-ID, 2007; Wachtel & Hagopian, 2006). Research shows that individuals with ID are 
frequently prescribed psychotropic medications to control problem behaviours without the 
presence or diagnosis of a mental illness (Bouras, 1999; Grey & Hastings, 2005; Matson, 
Bamburg, Mayville, et aI., 2000). Problem behaviours are a major concern for families, 
caregivers, and professionals in the field due to the negative impact behaviours can have on an 
individual's development and care. Severe problem behaviours can lead to decreased social 
opportunities, interfere with learning, and create economic challenges due to the high levels of 
needed supports (Wachtel & Hagopian, 2006). These individuals with ID and a mental health 
issue, psychiatric diagnoses, or severe problem behaviours are referred to as having a 'dual 
diagnosis', (Sturmey, Lindsay, Didden, 2007). There is a considerable amount of research with 
people who have dual diagnoses, and the use of psychotropic medications (daily and as needed) 
as a first line management approach is evident, although there are relatively few 
methodologically sound drug efficacy studies that include people with ID in their samples 
(Oliver-Africano, Dickens, Ahmed, Bouras et aI., 2010; Tyrer et aI., 2008). Furthermore, the 
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application of relevant research findings to actual clinical practice remains a challenge (Barnhill , 
2008; Matson & Neal, 2009). 
Purpose of Study 
This study addressed the current research and literature gaps by examining the related 
variables and rationales for psychotropic medication use (daily & as needed psychotropic use) in 
an Ontario based sample of individuals with ID. The study was a retrospective analysis, which 
examined data collected by residential agency managers from an existing database of 
information pertaining to 73 adults with a primary diagnosis of ID living in Ontario. At present, 
there is limited information in Canada, on the use of psychotropic medications for individuals 
with ID who are living in community residential settings or group homes (Lott et aI., 2004), 
although some previous studies have reviewed psychotropic drug use in Asian, European and 
American population samples (Aman, Sarphare, Burrow, 1995; Bisconer, Sine, Zhang, 1996; 
Holden & Gitlesen, 2004; Lott, McGregor, Engelman et al., 2004; Stolker et aI., 2001). The 
empirical evidence and rationales for the use of pharmacological interventions to address both 
problem behaviour and psychiatric disorders were reviewed (Grey, & Hastings, 2005; Sturmey, 
Lindsay, Didden, 2007; Wachtel & Hagopian, 2006). 
Significance of Current Study 
There is limited information within the literature on the prevalence of psychotropic 
prescribing practices in Canadian studies of individuals with ID living in the community. 
Existing research has not comprehensively examined individual characteristics, the presence, or 
absence of behaviour problems, prescribed as needed psychotropic medication use (PRN), 
rationales for different drug use, most common poly-prescribing combinations, or the other 
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therapeutic interventions in place in combination. Studies have not compared prescribing and 
monitoring practices to the standards of practice that are set forth in regions or countries of 
interest. 
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Understanding the patterns of psychotropic drug use could help residential support 
agencies develop ethical guidelines and monitoring processes, and ultimately work towards 
adhering to the 'Consensus Guidelines for Primary Health Care of Adults with ID' , CME (2006). 
Some of the anticipated benefits of this study include: (a) a heightened understanding of the 
prevalence and prescribing practices of psychotropic medications in this Ontario ID/DD sample; 
(b) the affiliated community agency will be provided with more meaningful information to: 
enable their effective program evaluation, improve tracking, monitoring, and review processes of 
medication use; (c) there will be a greater understanding of risk factors or predictors of 
psychotropic drug use in the individuals supported by the agency. These outcomes will also 
contribute to the field of developmental disabilities research in the areas of challenging/problem 
behaviours, psychotropic medication use. The findings of this study are expected to help 
improve services for individuals with ID and ultimately to positively impact participants' quality 
of life. This study will help bridge the gap between current research and practice in community 
agencies through the dissemination of the findings at the end of the study. 
Literature Review 
Throughout this paper the term 'Intellectual Disability' (ID) will be used to describe the 
diagnosis of individuals who have been referred to as having a Developmental Disability, (DD) 
or Mental Retardation, (MR) in the past (AAIDD, 2010). An ID is characterized by significant 
impairment in adaptive and intellectual functioning, expressed in practical, conceptual, and 
social skills, with an onset and diagnosis prior to the age of 18 years (AAID, 2010). The 
PSYCHOTROPIC MEDICA nONS AND ID 4 
following literature review will cover research and information in the areas of ID and mental 
health issues, problem behaviours, treatment of problem behaviours, psychotropic medications, 
efficacy and effectiveness research, prevalence studies, and consensus guidelines for the use of 
psychotropic medications. 
Intellectual Disabilities and Mental Health Issues 
Individuals with ID are identified to be at a greater risk to experience a psychiatric 
disorder or mental health issue compared to the general population (Chaplin, 2004; DM-ID, 
2007; La Malfa, Campigli, Bertelli, Mangiapane, et aI., 1997; Morin, Cobigo, Rivard, Lepine, 
2010). The risk factors (vulnerabilities) involved in the development of psychopathology in 
these individuals include: specific genetic syndromes; limited coping and communication skills; 
and behavioural phenotypes, which may include elements of psychiatric pathologies and aberrant 
(problem) behaviours (Bouras & Jacobson, 2002; Griffiths & King, 2004; Oliver & Hagerman, 
2007; Sturmey, Lindsay, Didden, 2007; Wachtel & Hagopian, 2006). The rates of psychiatric 
illness within this population are reported to range widely from 10% to as high as 80% 
(Verhoeven & Tuinier, 1997; Wachtel & Hagopian, 2006). This large range reflects ongoing 
challenges with accurate diagnoses of mental health issues (Morin et aI., 2010). Historically, 
there has been a lack of psychometrically sound instruments to accurately diagnose mental health 
disorders (Gardner, 2000). This has contributed to misdiagnosis, under-diagnosis, behavioural 
issues being managed with inappropriate pharmacological interventions, and or psychiatric or 
bio-medical issues being addressed with behavioural interventions alone (Gardner, 2000). 
Increases in problem behaviours, such as, aggression, self-injury, or property destruction 
are frequently the preceding factor for a psychiatric referral (DM-ID, 2007). One of the key 
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issues impeding accurate psychiatric diagnostic processes is the lack of experienced medical 
professionals dealing with individuals with ID, resulting in a decreased awareness, sensitivity, 
and ability to differentiate the psychiatric disorder from the disability itself (Gardner, 2000). 
Other diagnostic challenges are: the tendency of people with mild and moderate ID to try and 
hide their disabilities "cloak of competence", (Edgerton, 1967); difficulties accurately describing 
their experiences related to expressive and receptive language deficits; a tendency to tell an 
interviewer what they want to hear and thus answer questions falsely (referred to as 
"acquiescence bias") (DMID, 2007); challenging behaviour being attributed to the ID rather than 
a psychiatric disorder "diagnostic overshadowing", (Reiss, Levitan & Syszko, 1982); and 
assumptions that people with ID will have different symptoms of psychiatric disorders 
"psychosocial masking" (Sovner, 1986). The more commonly reported psychiatric disorders 
within the ID population include depressive disorder; anxiety disorder; bipolar affective disorder; 
conduct disorder; obsessive-compulsive disorder; and impulse control disorder (La Malfa, et aI., 
1997; Rojahn, J., et aI., 2003; Verhoeven & Tuinier, 1997). 
Assessment tools that enable more accurate diagnoses of mental health issues are now 
available, although their reliability and validity varies (Pomeroy, 2006). The difficulty 
interpreting the relative contribution of either the developmental disability or the mental health 
issues on the clinical presentation of an individual still occurs (Antochi, Stavrakaki, Emery, 
2003). However, several assessment tools have been modified and created to utilize more 
objective and behavioural diagnostic criteria. The Diagnostic Criteria for Psychiatric Disorders 
for Adults with Learning Disabilities/Mental Retardation, DC-LD, (Royal College of 
Psychiatrists, 2001) was developed to provide operational definitions for each of the criteria 
needed to determine the presence of psychiatric issues (DMID, 2007). The Diagnostic Manual 
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for Intellectual Disability (DM-ID) was recently published in 2007, and included objective 
behavioural indices in order to help facilitate more objective diagnosis of mental health issues 
experienced by people with ID and to improve research methodology (e.g., selection) in the area 
of dual diagnosis, and to increase appropriate treatment selection based on assessment outcomes 
(Ruedrich et aI., 2008). The longstanding diagnostic inconsistencies among professionals, has 
impacted research conducted in the dual diagnosis field with regard to research participants 
inclusion or exclusion, and treatment selection (Antochi, Stavrakaki, Emery, 2003). The 
treatment of psychiatric disorders in persons with ID ought to at least be as stringent as treatment 
of the general population (Deb, 2006). Treatment guidelines for the use of psychotropic 
medications for individuals with dual diagnoses must be updated and modified on an ongoing 
basis to increase the provision of the most effective evidence-based treatments. It is also 
important that clinicians understand that problem behaviours are not all symptomatic of existing 
mental health issues. 
Intellectual Disabilities and Problem Behaviours 
'Problem' or 'challenging behaviour' are umbrella terms used to describe a range of 
disruptive or dangerous behaviours in the ID population (Matson & Neal, 2009). Some 
examples of problem behaviours are: temper tantrums, verbal and physical aggression, 
screaming, property damage, and destruction, self-injurious behaviour (i.e. self-hitting, self-
biting, and skin picking), over activity, (Heyvaert, Maes, Onghenal, 2010). Because behavioural 
problems are prevalent in individuals with ID this creates many challenges throughout the 
lifespan (Mahan, Holloway, Bamburg, Hess, 2010; Sturmey, Lindsay, Didden, 2007; Wachtel & 
Hagopian, 2006). The impact of problem behaviours on the emotional, social, physical, 
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educational, and economic aspects of a person's life can lead to reduced opportunities for 
community involvement, educational placements, or habilitative programming (Heyvaert, Maes, 
Onghena1, 2010; Wachtel & Hagopian, 2006). The prevalence of behavioural problems has 
been reported to range from 10-31 % for self-injury, 7-30% for property destruction, and 2-28% 
for aggression (Wachtel & Hagopian, 2006). Behavioural problems have also been found to be 
more common in individuals with more severe ID or ASD, which may relate to a decreased 
ability to communicate or use effective coping strategies (McClintock, Hall & Oliver, 2003). 
Neurological models of behaviour attempt to explain the possible etiologies of some 
problem behaviours. These explanations underlie the use of psychotropic medications to address 
specific behaviours by associating neurotransmitter activity in the brain and the patho-
physiology of some behaviour (Matson, Mayville, Pinkston, et aI., 2000; Santosh, & Baird, 1999; 
Schroeder et aI., 1998). Self-injurious behaviour has three proposed neurological models: the 
opioid hypothesis; the dopamine hypothesis; and the serotonergic hypothesis (Baumeister & 
Sevin, 1990; Schroeder et aI., 1999; Symons, Thompson, Rodriguez, 2004). The dopamine (DA) 
depletion hypothesis was developed when post mortem brain analysis revealed that individuals 
with Lesch-Nyhan Syndrome (-100% prevalence of SIB) showed reduced indices of dopamine 
functions (Baumeister & Sevin, 1990). This hypothesis expects that DA antagonist drugs would 
inhibit SIB. However, since research conducted in this area is methodologically flawed, this 
hypothesis remains inconclusive (Baumeister & Sevin, 1990). The opioid hypothesis posits that 
two mechanisms of action are involved in SIB: a decreased sensitivity to pain, and an addiction 
to the release of endogenous opioids (Baumeister & Sevin, 1990; Matson, Mayville, Pinkston, et 
aI., 2000; Santosh, & Baird, 1999; Schroeder et aI., 1999). If self-injury is in fact influenced or 
maintained by the release of endogenous opioids, then an opiate antagonist, which blocks opioid 
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receptors, would be expected to attenuate SIB (Symons, Thompson, Rodriguez, 2004). 
However, there is only limited literature supporting the efficacy of N altrexone (opioid 
antagonist) to decrease self-injurious behaviour (Schroeder et aI., 1999; Symons, Thompson, 
Rodriguez, 2004). 
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Animal research has also implicated involvement of the serotonergic system with problem 
behaviours, such as, aggression and self-injury (Thompson & Symons, 1999). A decreased level 
of serotonin (5-HT) in animal brains was related to the presence of aggressive or self-injurious 
behaviours (Thompson & Symons, 1999). Therefore, the application of a psychotropic drug to 
increase the level of serotonin would be expected to decrease these behaviours. However, there 
is no conclusive evidence supporting this hypothesis. 
The proposed neurological model for general destructive behaviours loosely involves the 
dopaminergic system. Studies indicated that dopamine (DA) modulation, primarily the sedation 
effects of DA acting drugs (antipsychotics), decreased destructive behaviours in some cases 
(Thompson & Symons, 1999). The administration of antipsychotic drugs was hypothesized to 
reduce the reinforcer effectiveness (positive or negative) that may be involved in maintaining 
destructive behaviours (Thompson & Symons, 1999). Although these models provide theoretical 
hypotheses about modifiable relationships between brain and behaviour, they do not clearly 
indicate causal relationships nor do they consider other possible contributing factors, such, as 
operant motivations. Although it is appropriate to consider neurological models of behaviour 
before selecting a pharmacological interventions, neurological models on their own do not 
sufficiently explain or address all the complex factors which may be involved in the origin or 
maintenance of problem behaviours (Barnhill, 2008; Matson & Neal, 2009). 
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Behaviours can also be learned and maintained through interactions with the physical and 
social environment (Cooper, Heron, Heward, 2007). Behaviours that are learned or maintained 
through reinforcement contingencies are referred to as operant behaviours. A person's ability to 
effectively communicate their needs, deficits in adaptive, social, or coping skills, underlying 
mental health issues, genetic syndromes, and the support qualities of their living environments 
can influence behaviour (Cooper, Heron, Heward, 2007; Sturmey, 1995; Gardner, 2002). 
Antecedent stimuli can also act as triggers for problem behaviour or they can act as 
environmental conditions or setting events that affect the likelihood of the occurrence of 
behaviour (Horner, Day & Day, 1997). A functional behavior assessment (FBA) is an 
assessment technique which can be used to form a hypothesis about the "function or purpose" of 
a specific behavior (Cooper, Heron, Heward, 2007; Herzinger & Campbell, 2007). The outcomes 
from FBA's can be used to facilitate the development of appropriate treatment interventions to 
meet the communicative and functional needs of individuals with problem behaviours (Herzinger 
& Campbell, 2007). 
A thorough bio-psycho-social assessment of an individual prior to treatment planning 
would help identify any root causes or influences on an individual's behaviour or clinical 
presentation that may be related to a medical, psychiatric, or learning based issues (La Malfa, 
Lassi, Bertelli, Castellani, et aI., 2006; Tsouris, 2009). A bio-psychosocial approach would also 
help prevent over-attribution of behaviour problems as markers of a psychiatric disorder, or 
behaviour problems being considered a part of a disability when in fact there may be a 
psychiatric component (La Malfa, Lassi, Bertelli, Castellani, et aI., 2006). A thorough 
assessment would also assist to identify any behavioural problems, which may serve an operant 
function (La Malfa, Lassi, Bertelli, Castellani, et aI., 2006). A better understanding of the root 
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causes of problem behaviour would help a clinician justify their treatment decisions, or to use, or 
not use, a psychotropic medication to decrease undesirable behaviours. This would also decrease 
the chance that psychotropics medications would function as a chemical restraint (Matson et aI., 
2000). 
Psychotropic Medications and Intellectual Disabilities 
As early as the 1950s, psychopharmacological drugs were prescribed to individuals with 
ID, primarily for their general sedative effects and in the absence of available research on 
efficacy (Schroeder et aI., 1998). The use of psychotropic medication to treat individuals with 
ID became even more prevalent during the 1970s and 80s (Schroeder et aI., 1998). Historically, 
research in the area of ID and psychopharmacology was lacking due to funding issues and 
legislation protective of this population (Schroeder et aI., 1998). 
Classes of Medication 
There are several categories of psychotropic medications used to address psychiatric 
disorders or problem behaviours in individuals with ID. The general goal of psychotropic 
interventions are the altering of neurological systems in order to decrease undesirable symptoms 
or mood states, to modulate neurotransmitter activity, and to alter central nervous system 
functions (Pointedexter, 2002). The majority of psychotropic medications being prescribed for 
individuals with ID fall into the following medication classes: neuroleptics (antipsychotics); anti-
epileptics; antidepressants; anxiolytics and sedatives; mood stabilizers; opioid blockers; and 
beta-adrenergic blockers (Kern, 1999, p.103; NIMH, 2010). The most common 
psychopharmacological drugs from each class, the suspected neurological effects, and common 
reasons for administration are presented in Appendix A. 
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Rationales for Psychotropic Medication Use 
The rationales for the use of pharmacological interventions by persons with ID and 
psychiatric disorders has to date been explained by the research on the neurotypical mental 
health population (Matson et aI., 2000; Spreat, Conroy, Jones, 1997). In the treatment of mental 
health issues there is evidence that psychotropic medications can reduce underlying adverse 
mood states, and thereby decrease the impact of external antecedent or triggering conditions 
(Deb et aI., 2007; Gardner, 2008). However, there is ongoing concern that the variability in 
neurological, cognitive, or behavioral impairments, makes individuals with ID more susceptible 
to adverse side effects (Mahan, Holloway, Bamburg, Hess et aI., 2010). These neurological and 
cognitive differences in persons with ID question the premise that the effectiveness of 
psychotropic medication can be directly predicted from the effects seen in the neurotypical 
population (Baumeister & Sevin, 1990). Some literature has shown successes in treating 
symptoms specifically related to psychiatric disorders, however, individuals with ID are most 
frequently prescribed psychotropic medications to control problem behaviours (reference), and 
often without the actual presence or diagnosis of a mental illness (Bouras, 1999; Grey & 
Hastings, 2005; Matson, Bamburg, Mayville, et aI., 2000). Research suggests that when 
psychotropic medications are used in the absence of a mental health issues they can sometimes 
decrease problem behaviours, however, they may actually be suppressing behaviour and thereby 
interfere with the identification of other possible root causes of behaviour, such as, deficits in 
communication or other skills (Allen, 2008; Brylewski & Duggan, 1999; Tyrer, 2008, Kuijper et 
aI., 2010). Nevertheless, the use of pharmacological interventions for individuals with ID 
remains widespread (Nottestad & Linaker, 2003; Deb et aI., 2009). 
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Treatment of Problem Behaviours 
The gradual closure of residential institutions over the past three decades has brought to 
light the importance of finding and implementing effective and sustainable community based 
treatment strategies for individuals with ID (Burd, Williams, Klug, Fgelstad, 1997). The use of 
psychopharmacological drugs has continued to be prevalent, irrespective of assessment 
challenges or the presence or absence of a psychiatric diagnosis (Sturmey, Lindsay, Didden, 
2007). Problem or severely disruptive behaviours can be difficult to address in some community 
settings, which may have limited resources (Wachtel & Hagopian, 2006). Researchers have 
suggested that the high rates of psychotropic reliance may be related to medical services being 
more available and accessible than alternative or psychological services. Moreover some 
researchers assert that in place of long-term therapeutic intervention, practitioners continue to 
address problem behaviours in a reactive way (La Malfa, et aI., 2006; Matson & Minshawi, 
2007; Matson, Mayville, Pinkston, et aI., 2000; Matson et aI., 2000; Santosh, & Baird, 1999; 
Tsakanikos, Costello, Holt, et aI., 2007). 
Currently, both pharmacological and behavioural interventions are the two dominant 
treatment approaches used to address the problem behaviours of individuals with ID (Gardner, 
2000; Matson & Neal, 2009; Matson & Wilkins, 2008). Both approaches have been found to 
have merit in different contexts, although they are not often used cooperatively or as part a 
multidisciplinary plan (Matson & Wilkins, 2008). In fact the implementation of either 
pharmacological or behavioural interventions for problem behaviours have been found to 
directly relate to the place of primary residence, as well as, the availability or accessibility of a 
psychiatrist experienced in working with individuals with ID, or appropriate behavioural services 
(Jacobson & Bouras, 2002; Matson & Wilkins, 2008). Limited accessibility and resources can 
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decrease the chances that individuals will receive the most appropriate evidence based treatment 
(Bradley & Cheetham, 2010). Applied Behaviour Analysis utilizes functional assessment 
methodologies to examine operant explanations for behaviour (functions) (Hanley, Iwata, 
McCord, 2003). Research has shown that behavioral interventions based on functional 
assessment results can effectively decrease rates of problem behavior in persons with ID (Carr & 
Durand, 1985; Matson, Copper, Malone, Moskow, 2008; Heyvaert, Maes, Onghena1, 2010). 
There are also a few studies that reported some efficacy of pharmacological interventions for the 
management of problem behaviours, however, most studies (see next section) are 
methodologically flawed and thus their claims are weak at best (Deb et aI., 2007; La Malfa, et 
al., 2006; Matson et aI., 2000; Matson et aI., 2003; Matson & Neal, 2009). 
Off Label Use 
Research has also revealed that individuals with ID are often prescribed drugs for off-
label indications (Baumeister, Sevin, King, 1998, p. 147). 'Off Label' medication use refers to 
the prescribing of drugs for issues outside the marketing or licensed authorization, or for a dose 
in excess of the marketing authorization, such as, an anti-psychotic being given to address a 
depressive disorder, despite literature indicating the first-line use of an antidepressant (Haw & 
Stubbs, 2005). Essentially, what this means is that many psychotropic drugs have not been 
examined for risks, benefits, efficacy, or side effects for these 'off-label' uses (Haw & Stubbs, 
2005). Although off-label prescribing has been described as a common practice within the field 
of psychiatry and the typical population, this rationalization does not seem ethical for more 
vulnerable or special groups, such as, children and people with ID (Haw & Stubbs, 2005). In 
addition, getting informed consent from patients to take a drug that has been prescribed for an 
off-label reason is imperative, and this can be a challenge with individuals with ID who may 
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have communication issues or a limited capacity to understand the meaning of off-label and the 
idea of a risklbenefit ratio (Haw & Stubbs, 2005). In a 2005 study conducted on 56 in-patients 
from an ID division of a charitable hospital with mild ID and mental illness, 46% were found to 
be receiving a minimum of one off-label psychotropic medication (Haw & Stubbs, 2005). The 
most prevalent rational for the off-label prescribing was reported to be the reduction of 
aggression, arousal, behavioural disturbance, and mood stabilization (Haw & Stubbs, 2005). 
These off-label uses suggest that some medications are being used for their secondary sedative 
effects rather than the intended primary therapeutic effects (Allen, 2008). The field of 'Dual 
diagnosis' would benefit from more methodologically sound research, to specifically investigate 
the effectiveness of psychopharmacological treatments within this vulnerable population. 
Side Effects 
There are many known side effects of psychotropic medications. Detecting side effects is 
difficult in individuals with ID because they may not be able to effectively communicate their 
psychological states, they may not be aware of the side effects to look for, drug related 
experiences and their disability may also mask some signs of toxicity (Deb et aI., 2009; Mahan, 
et aI., 2010; Matson et aI., 2000; Stavraki et al., 2002). For example, individuals may also have a 
hard time expressing unpleasant or adverse effects to their caregivers, or stereotypic behaviours 
may be misinterpreted as part of a disability rather than a drug-induced movement (Stavraki et 
aI., 2002). It can also be difficult to measure mood changes, or the worsening of other problem 
behaviours, following medication administration (Valdovinos, et aI., 2005). Nonetheless side 
effects are an important consideration when using psychotropic drugs. The careful monitoring of 
side effects is recommended (Matson, Rivet, Fodstad, 2008). All medications carry both risks 
and benefits, therefore, the intended therapeutic impact or outcome may be influenced, negated, 
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or compromised by secondary effects of the medication. Side effects can potentially impact: 
medication non-compliance, increased behaviour problems, quality of life, impaired cognitive 
functioning, interference with learning (Kalachnik, 1999). 
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The development of the newer classes of atypical antipsychotic medications and 
antidepressants, Selective Serotonin Reuptake Inhibitor, (SSRIs), has reduced the associated side 
effect profiles (Ruedrich et aI., 2008; Singh et aI., 2005). However, currently they are no 
accepted standardized methods recommended to most effectively recognize and monitor side 
effects in this population and thus this area warrants further attention and guidelines. Without 
careful medical or program monitoring systems in place, there is a high risk that any short-term 
benefits of psychotropic medications can easily become long-term treatments or management 
approaches (Manchester, 1993). The 'International Guide to Prescribing Psychotropic 
Medications for Problem Behaviours' has also recommended that consideration be given to the 
impact of the medication on the quality of life of the treated individual, to ensure it is ethical to 
continue (Deb, 2007). It is important to clarify who will be monitoring for any negative side 
effects of the medications and how the monitoring will be done (Deb, 2006). The ability to 
effectively recognize and monitor side effects in this population remains a challenge. 
Psychotropic Medications: Efficacy and Effectiveness Research 
In clinical research, the accepted 'Gold Standard' research design is a double-blind 
randomized controlled trial (ReT). Standards propose that efficacy data refer to double-blind 
and placebo controlled studies that have a random assignment of participants to the treatment 
conditions; including both baseline and reversal phases (ABAB designs) when ethically possible; 
and that they utilize single and within subject designs, as well as, direct objective measures of 
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behaviour change and side-effects (Baumeister & Sevin, 1990; La Malfa, et aI., 2006). The term 
polypharmacy or poly prescribing can either describe the prescribing of more than one 
psychotropic medication for a particular indication, i.e. a behaviour problem or the prescribing of 
more than one psychotropic medication to an individual (Deb, 2006). 
In their 2006 review, La Malfa et aI. examined 195 studies on pharmacology and ID for 
methodological rigour and efficacy reports about psychotropic medications. They found that 
efficacy reports of the pharmacological interventions for problem behaviour were primarily 
based on case reports, consensus documents, case reviews, expert or consensus opinions, and 
general reviews of literature; only 21 of the 195 studies utilized RCTs with follow-up. Many 
studies also neglected to report whether there were any considerations about the underlying 
causes (psychiatric) or functions of problem behaviours before pharmacological interventions 
were initiated (Deb et aI., 2007). 
The main methodological problems identified with published clinical studies in the area 
of pharmacology and ID, were: a lack of objective measures to evaluate the efficacy of the 
medications; heterogeneous samples and outcomes measures, inadequate reporting of negative 
side-effects; and the absence of behavioural assessments prior to mediation administration 
(Dinca, Paul, Spencer, 2005; Matson & Neal, 2009; Oliver-Africano, Dickens, Ahment, 2010). 
There is also a limited body of data concerning the effects of psychotropic medications across all 
sub-classifications of pervasive developmental disorders and ID, across different age categories, 
looking at short, medium, and long-term effects, and the overall impact on the quality of life of 
the treated individuals (Dinca, Paul, Spencer, 2005). There are also ongoing recruitment 
challenges related to participant accessibility, consent/assent issues, heterogeneity of 
participants, and attitudes toward treatment (Dinca, Paul, Spencer, 2005; Oliver-Africano, 
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Dickens, Ahment, 2010). Since the studies on the treatment of problem behaviour or mental 
health issues with psychotropic medications in individuals with ID have these methodological 
constraints, it is imperative that the findings are interpreted with caution. 
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Recently there have been increased efforts within the scientific and medical communities 
to completed more ReT efficacy studies in the area of psychotropic medications for individuals 
with ID (Oliver-Africano, Dickens, Ahment, 2010). However, results from these studies continue 
to be mixed. For example, in 2005 and 2006 a few ReT studies were shown to support the 
efficacy of Risperidone for the management of aggression or general problem behaviours in both 
children and adults with ID (Deb, 2006; Gagliano, Read, Thorpe, et aI., 2005; Grey, & Hastings, 
2005). At that time, Haloperidol (conventional antipsychotic) was still identified as the most 
widely prescribed antipsychotic drug (La Malfa, et aI., 2006). Since then, two ReT studies 
comparing the effects of Risperidone, Haloperidol, and placebo, in the treatment of aggressive 
behaviour in individuals with ID found that all three agents had a reduction in aggression at 4 
weeks, however, the placebo group had the largest decrease in aggressive behaviours and was the 
most cost effective (Tyrer et aI., 2008; Tyrer, Oliver-Africano, Romeo, Knapp, 2009). 
In a 2009 review, Matson & Neal examined 56 drug efficacy studies with people with ID 
and problem behaviours. Only 23 of the studies met the criteria of double blind, placebo 
controlled procedures, and only 12 met the additional criteria of random assignment. The 
efficacy results of the 12 double blind, placebo controlled and randomly assigned studies were 
mixed and thus inconclusive. Furthermore, the stringent studies examining the effectiveness of 
psychotropics on behaviour reduction (i.e. ReT + more objective behavioural change measures), 
tended to report less effects or 'no change' when compared to placebo (Matson & Neal, 2009; 
Tyrer et aI., 2008). Thus it is becoming increasingly clear that studies with more rigorous 
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experimental designs and objective behavioural outcome measures are less likely to support 
psychotropic medications as efficacious for the treatment of problem behaviours in persons with 
ID (Matson & Neal, 2009). 
Research clearly shows that there is currently no drug specific evidence to recommend 
the use of one particular medication over another for problem behaviours in persons with ID 
(World Psychiatric Association, 2009). Additionally, most psychotropic drugs are not officially 
licensed or approved to treat challenging behaviours (Deb et aI., 2007). Also the large number of 
different psychotropic medications makes it difficult to make general efficacy claims due to the 
lack of testing done with each different medication. Research findings from one particular 
medication or medication class do not necessarily generalize to other psychotropic medication in 
the same class. Although methodological rigor has improved, there continue to be individual 
recruitment issues, a lack of efficacy studies on the wide variety of different medications, 
including functional assessments and objective outcome measures, with long treatment follow 
ups, clear reporting of related adverse side effects (Oliver-Africano, Dickens, Ahmed, Bouras, et 
aI., 2010; Matson & Neal, 2009; Tyrer et aI., 2008). 
In conclusion, the mixed results, the diverse number of different psychotropic medications, 
and the few studies with rigorous control procedures highlight the importance of exercising 
caution with regard to the use of psychotropic medications for the management of problem 
behaviours in persons with ID (Matson & Neal, 2009). Although the methodological rigor of 
some recent studies has improved, there continues to be a challenge with individual recruitment, 
a lack of follow ups, inconsistent reporting of adverse side effects, and short experimental trials 
(Matson & Neal, 2009; Oliver-Africano et aI., 2010). Literature continues to indicate that 
problem behaviours are consistent predictors for the use of psychotropic medications in adults 
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with ID despite the above-mentioned concerns (Aman, Sarphare & Burrows, 1995; De Kuijper et 
aI, 2010; Holden & Gitlesen, 2004; Singh, Ellis & Wechsler, 1997; Tsakanikos, Bouras, 
Costello, & Holt, 2007). 
Prevalence of Psychotropic Medication Use 
The prevalence of psychotropic medication use in individuals with ID who are living in 
community settings, ranges widely. An American community-based study conducted in 1995 
reported that 27% of 1101 individuals with ID living in a group home, were prescribed one or 
more psychotropic drugs for behavioural or emotional disorders, and 12% were prescribed 
between two to five drugs (Aman, Sarphare, Burrow, 1995). The researchers also made several 
interesting discoveries. They found no relationship between existing diagnoses and medication 
use from the related drug treatment class, i.e. depression -7 anti-depressant medication, no 
correlation between age and prevalence of psychotropic medications, and no gender effects for 
total psychotropic use. Individuals with more severe levels of ID were found to receive less 
psychotropic medications. They also reported that participants with diagnosed seizure conditions 
received less psychotropic medications prescribed for behaviour control (although many had 
psychotropic medications prescribed for seizure control). 
Examination of rationales to use the drugs revealed that many of the drugs were used to 
address concerns or symptoms for which the drug use had not been established or approved 
empirically. Aman et al. concluded that there was no empirical support for the safe or effective 
use of anti-psychotics/neuroleptics for these behavioural issues. Burd, Williams, Klug, Fjelstad, 
et al. (1997), found that 38% of 1384 individuals with ID had psychotropic medications 
prescribed and 11 % had more than one psychotropic prescribed. They also found a significant 
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relationship between the use of polypharmacy and psychiatric diagnoses. Spreat, Conroy, 
Fullerton, & Bodfish (2004) conducted a longitudinal survey of psychotropic medication use in 
individuals with ID between 1994 and 2000. They found that in 2000,35.4% of the 3187 
individuals with ID were receiving psychotropic medications. An examination of the classes of 
prescribed psychotropics showed that approximately 20% of adults were being prescribed 
antipsychotics, 15.8% antidepressants, and 11.1 % anxiolytics. 
Another American study conducted in 2004 examined the longitudinal prescribing 
practices for psychoactive medications for 2344 persons with ID over a 17 -month period, using 
pharmacy records (Lott, McGregor, Engelman, Touchette et aI., 2004). Their results showed that 
52% of all prescriptions were for psychoactive medications. Antipsychotics, antidepressant and 
anticonvulsant medications were revealed to be the most commonly filled prescriptions. Sixty-
two percent of the individuals in their study were prescribed more than one psychoactive 
medication and 36% received three or more psychoactive medications (Lott, McGregor, 
Engelman, Touchette et aI., 2004). Their study did not report any comparative information 
regarding the rationales for drug prescriptions. 
Studies conducted in the Netherlands by van Schrojenstein Lantman-de Valk et aI., 
(1995) and Stolker et aI., (2002) found the prevalence of psychotropic medication use to be 24% 
and 17%, respectively, for individuals with ID living in group homes. Stolker et aI., (2002) also 
noticed that 17% of the 573 individuals identified as having 'problem behaviours', were 
prescribed multiple (3 or more) drugs compared to the no-problem behaviour control group who 
were only prescribed multiple psychotropic drugs at a 7% rate. A recent cross-sectional study 
from the Netherlands showed that the prevalence of antipsychotic drug use in 2373 individuals 
with ID living in the community was 32% (De Kuijper et aI., 2010). The study examined 
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pharmacy records to determine the prevalence of psychotropic medication use in this population 
(De Kuijper et aI., 201 0). They found that the main rationale for drug prescriptions were 
behavioural problems, in 58% of cases, and secondly, for a psychotic disorders or symptom in 
5% of cases. 
In a 2004 Norwegian study, researchers looked at the prevalence of psychotropic 
medication use in 300 people with ID living in the community (Holden & Gitlesen, 2004). Their 
results showed that 37% of the individuals used psychotropic medications. They also found that 
26% of individuals used one medication, 9% used two, and 2% used three medications. 
Neuroleptics (also referred to as antipsychotics) were identified to be the most frequently 
prescribed psychotropic medications, then antidepressants, and then anticonvulsants. The most 
common rationales identified for the medications prescribed in their study were aggression, self-
injury, destruction of property, and non-compliance. Only half of the psychotropic prescriptions 
in this Norwegian sample were indicated by a psychiatric diagnosis. 
In a published Australian study, researchers examined the changes in psychotropic drug 
use across time by comparing a sample from 1993 to 2000 (McGillivay & McCabe, 2006). Their 
study examined the prevalence and types of psychotropic drugs used to manage behaviours. The 
results showed a decrease in antipsychotic use and increase in anti-convulsant and antidepressant 
use from 1993 to 2000. The results of the 2000 sample of 873 individuals who were identified as 
"chemically restrained" (p.165) found that, 83% were prescribed antipsychotics; 18.% anti-
anxiety; 16% anticonvulsant; 21 % anti-depressants (McGillivay & McCabe, 2006). 
Furthermore, the number of drugs received per individual increased from 1993 to 2000, 1.39 to 
1.54 respectively. The rates of polypharmacy in both samples ranged from 29% to 38% 
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(McGillivay & McCabe, 2006). This study highlights the widespread polypharmacy within these 
samples and across time. 
The main findings of the above studies in North America, Australia, and Europe revealed 
that the general prevalence of psychotropic medication use in people with ID ranges from 16 to 
83%. There is still limited information looking at the conditions under which psychotropic 
medications are prescribed, the rationales for use, and regarding the evaluation and outcome 
monitoring practices. The aforementioned studies have provided some insight into the patterns 
of psychotropic drug use in community samples of persons with ID, however, most of the studies 
utilized different data collection methods, which may account for the range in rates. The ranges 
in prevalence of use may also reflect different standards or routines practices across countries 
and samples. 
Consensus Guidelines for the Use of Psychotropic Medications 
Guidelines have been developed to assist physicians or other health care professionals to 
better understand the behavioural issues and to help with treatment planning (Sullivan et aI., 
2006). A recent update to the 2006 Primary Care of Adults with Developmental Disabilities: 
Canadian Consensus Guidelines (Sullivan, Berg, Bradley, Cheetham, et aI., in press) regarding 
behavioural and mental health, rejects the routine use of antipsychotic medications for problem 
behaviours (specifically, aggressive challenging behaviour) without a confirmed robust diagnosis 
of schizophrenia or other psychotic disorder. Guidelines from the University of Birmingham in 
the United Kingdom recommend that psychotropic medication only be prescribed if: a) based on 
sound empirical evidence; b) after considering and addressing consent issues; c) ensuring a 
functional assessment is completed if possible before using psychotropic medications for 
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psychiatric or behavioural issues; d) objectively measuring treatment outcomes; e) ensuring 
careful monitoring for potential side effects of treatment; f) conducting frequent and thorough 
reviews of progress with colleagues; and g) that they use the lowest optimal dose of medication 
possible (Deb, 2006). 
Treatment guidelines for the use of psychopharmacology for individual with co-morbid 
intellectual disabilities, mental health, or behavioural issues must continue to be updated and 
disseminated to physicians and other clinicians on an ongoing basis to increase the provision of 
the most effective evidence-based treatments. There is a pressing need for medical professionals 
to adequately consider all the risks, as well as, potential benefits of pharmacological 
interventions prior to prescribing to persons with ID. A national survey of psychotropic drug use 
for the management of problem behaviours revealed that in 2010 in Canada there were no 
mandated policies or guidelines on use of psychotropic medication for the management of 
problem behaviours either provincially or nationally (Bradley & Cheetham, 2010). Furthermore, 
it is not a prerequisite for physicians who are prescribing psychotropic medications to individuals 
with ID to have training or experience working with this vulnerable group (Bradley & Cheetham, 
2010). Despite being published in 2006, the guidelines recommended by Sullivan et aI, are not 
mandated. 
Summary 
Research has shown that individuals with intellectual disabilities (ID) are at an increased 
risk to develop both mental health issues and behavioural problems across the lifespan (Sturmey, 
Lindsay, Didden, 2007). Studies from North America and Europe have shown that rates of 
psychotropic medication use in people with ID has remained high, 16 to 83% during the past two 
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decades (Aman, Sarphare, Burrow, 1995; Burd, Williams, Klug, Fjelstad, et aI., 1997; De 
Kuijper et aI., 2010; Holden & Gitlesen, 2004; Lott, McGregor, Engelman, Touchette et aI., 
2004; McGillivay & McCabe, 2006; Spreat, Conroy, Fullerton, & Bodfish, 2004; Stolker et aI., 
2002; van Schrojenstein Lantman-de Valk et aI., 1995). Furthermore, psychotropic medications 
are most frequently prescribed to control problem behaviours without the actual presence or a 
diagnosis of a mental illness in individuals with ID (Bouras, 1999; Grey & Hastings, 2005; Haw 
& Stubbs, 2005; Matson, Bamburg, Mayville, et aI., 2000; Matson & Neal, 2009). Many 
researchers examining the use of psychotropic medications for the management of problem 
behaviours report that the current literature includes many studies that are methodologically 
flawed and thus limiting the quality of evidence (Deb et aI., 2007; La Malfa, et aI., 2006; 
Matson et aI., 2000; Matson et aI., 2003; Matson & Neal, 2009). Currently, no studies have 
comprehensively examined and reported on factors such as, individual characteristics, patterns of 
psychotropic usage over time, the presence or absence of behavioural problems and behaviour 
plans, rationales for different drug use, most common poly-prescribing combinations, or 
characteristics of PRN usage, within the same sample of individuals with ID. This study has 
attempted to address the current research and literature gaps by examining the psychotropic 
medication use in an Ontario based Canadian sample of individuals with ID. 
Research Questions and Hypotheses 
The purpose of this study was to examine changes and patterns of psychotropic 
medication use over a one-year period for a group of 73 adults with a primary diagnosis of ID 
living in the community. This study brought together current information on prevalence and 
prescribing patterns, with current prescribing guidelines/standards regarding the use of 
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psychopharmacology in this population. This study was designed to answer the following 
questions: 
1. What are the characteristics of people who are taking psychotropic medications? 
2. What are the rates and patterns of psychotropic medication use? 
3. What are the documented reasons that psychotropic medications are prescribed? 
4. Does psychotropic medication use for this sample of individuals living in community 
residential settings adhere to the guidelines recommended in the 'Consensus guidelines 
for primary health care of adults with developmental disabilities' (CME,2006) 
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5. What are the relationships between client characteristics and psychotropic medication use 




This study is a retrospective, longitudinal cohort study on psychotropic medication use 
over a year period in a sample of individuals with ID living in a community residential setting. 
Participants 
The sample consisted of individuals residing in residential group homes operated by a 
community agency. This agency provides residential housing and day programs to 
approximately 75 individuals, ranging in age from 21 to 68 years, with varying degrees and types 
of ID living in the Durham Region of Ontario, Canada. Database information was available for 
76 individuals; however, only individuals living within the agency group homes during the entire 
period from February 2009 to February 2010 were included in the study. Three individuals were 
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excluded from the original n of 76. Of these, one passed away during the course of the year 
being examined, and two were newly admitted part way through the year. Data for 73 
participants were included in the analyses. Informed consent was obtained from the participants 
as a part of their service agreement with the agency when they first entered care. Consent was 
obtained from the participants or their substitute decision makers for the collection of data to 
permit the agency to complete program evaluation and to investigate aspects of care for service 
improvement purposes. The data that were provided for this project was anonymous, and 
adhered to individual client consent and privacy issues as indicated in the Freedom of 
Information and Protection of Privacy Act (FIPPA), R.S.O. 1990, CHAPTER F.31, s. 21 (1) & s. 
41 (1). The study was consistent with the program evaluation efforts of the' Community Living' 
agency and the results will provide information to continuously improve the quality of services. 
Permission for this study was granted from the Brock University Research Ethics Board for the 
secondary analysis of these data. 
Data Collection 
The data were collected from a database maintained by a community living agency for 
the purposes of: tracking medication, client treatment information and to enable monitoring for 
quality control purposes. These data included: individual demographics, incidents reports, 
medication errors, prescribed medications, medical/psychiatric diagnoses, treatment strategies; 
and to provide monthly information for managers to be able to review and supervise their 
residential programs. The primary student investigator assisted in the design, maintenance, 
analysis and interpretation of the database as part of her job as a Behaviour Consultant prior to 
the start of this study. Medication information included: name of medication, dose, route of 
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administration, and rationale for use, start date, date of recent medication review (past or future) 
for general health and psychotropic medications. Individual characteristics included: primary 
and secondary diagnoses, presence or absence of problem behaviour (may have one or more of: 
verbal aggression, physical aggression, self-injury, sexuality inappropriate, property destruction), 
presence of formal behaviour plans, rated intensity of support (based on Accreditation Ontario 
Classifications (minimal, limited, intermittent, intensive, extensive), individual monthly rates of 
incidents or 'pro re nata' (PRN) medication use. The database included additional information 
(i.e. medication errors, incident reports) however these data were not relevant to the research 
questions of this study. 
Group home managers provided and updated the information about client profiles and 
treatment plans, contained within the database, to the information data coordinator, on a monthly 
basis. Individual medication information was documented on medication information sheets, 
which were provided by the pharmacy to the group homes, and then forwarded to the 
information data coordinator on a monthly basis. The accuracy of data provided by the managers 
was not checked routinely, unless obvious discrepancies were noticed. To ensure anonymity of 
participants, the information contained in the database did not include any personal identifiers, 
and was coded using numbers. Personal identifiers were not revealed or disclosed at any point 
during the study. The community living agency provided the student investigator with the excel 
database spreadsheets without identifying information. 
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Procedure 
1. REB clearance was obtained for the secondary use of the data 
2. Data were coded according to the medication categories: 1) general health, 2) all 
psychotropic medications. 
3. The medications were then coded according to their rationale for use and drug 
classification (NIMH, 2008). 
a. The rationales included: anxiety, mood, psychiatric disorder, seizure control, 
behaviour control/no-psychiatric diagnosis. 
b. The medication classifications were as follows: first generation anti-psychotics 
(i.e. haloperidol, methotrimeprazine, perphenazine); second generation anti-
psychotics (i.e., risperidone, quetiapine, olanzapine); antidepressants (i.e., 
fluoxetine, sertraline, bupropion, desyrel (Trazodone), mirtazapine, 
escitalopram, citalopram, venlafaxine, imipramine, fluvoxamine, paroxetine); 
anti-anxiety medications (i.e. lorazepam, clonazepam, diazepam, alprazolam, 
oxazepam); anti-convulsants/mood stabilizers (i.e., carbamazepine, divalproex 
sodium, valproic acid, clobazam, dilantin, lithium carbonate, lamotrigine, 
gabapentin, zarontin, primidone, benzotropine (for seizures), oxecarbazepine, 
nitrazepam, levetiracetam); hypnotics (i.e., zopiclone); and stimulants (i.e., 
methylphenidate) (NIMH, 2008). 
4. Data was tallied for February 2009, May 2009, August 2009, November 2009, and 
February 2010. 
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5. The duration of use of each psychotropic drug was determined in excel using the start 
date: The duration categories were as follows: 0-6 months, 6-12 months, 1-5 years, 5-
10 years, or > 1 0 years. 
6. Individual participant totals for February 2009 were imported into P ASW for further 
analysis. 
Statistical Analysis 
Statistical analyses were completed using PASW version 18.0 and some descriptive 
analyses were completed using Excel 2007. PASW was used to calculate descriptive statistics: 
frequencies, sums, means, standard deviations, variance, distribution SD, skewness or kurtosis, 
and range. P ASW was used to explore relationships between participant characteristics and the 
number of prescribed psychotropic medications. Continuous variables were correlated using 
Pearson's Correlation Coefficient r. Nominal variables were correlated using Phi. Where 
continuous variables were correlated with nominal variables, point-biserial correlations were 
completed in PASW using Pearson's r (Field, 2009; Thompson, 2006) as there is no 
mathematical difference and the results would be identical (DeCoster, 2004). 
Results 
Characteristics of Sample Population 
The sample included 73 participants, described in Table 1 below. The majority of people 
in the sample had no known etiology for their ID. Thirty-one individuals were identified as 
having seizures, although only 14 individuals had a formal diagnosis of Epilepsy. 
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Table 1 
Demographic and clinical characteristics of the study participants 
Participants (n=73) 
Characteristics Frequency Percentage 
Gender 
Male 43 59 
Female 30 41 
Age M45.9 (SD 10.4) 
Primary Diagnoses 
ID Unknown Etiology 56 77 
ID Known Etiology 17 23 
Autism 7 10 
Down syndrome 8 11 
Cerebral Palsy 7 10 
Secondary Diagnoses 
Seizures 31 19 
Psychiatric Diagnosis 12 16 
Problem Behaviours 
Yes 44 60 
Support Level Needs 
Minimal 11 15 
Intermittent 8 11 
Limited 6 8 
Intensive 22 30 
Extensive 20 27 
Unknown 6 8 
Note. Participant ages range from 21-68. 
More than half the participants in this study were identified as having problem 
behaviours. The most prevalent problem behaviours were verbal and physical aggression, self-
injury, and property destruction. The varieties of problem behaviours are presented below in 
Figure 1. Some individuals have more than one identified problem behaviours. 
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Figure 1. Prevalence of identified problem behaviours within this sample 
Rates and Duration of Psychotropic Drug Use 
The first available month of data (February 2009) was used to determine rates of 
psychotropic medication use. In the study sample of 73 participants, 61 participants (83.6%) 
were prescribed psychotropic medications (including seizure medications) and 54 (74%) were 
prescribed two or more psychotropic medications (polypharmacy; Deb, 2006). From this group 
of 61,41 individuals (67%) had identified problem behaviours. There were 31 participants 
(43%) who were prescribed medications for seizure control, of whom only 14 had formal 
diagnoses of Epilepsy. Individuals in the 'psychotropic medication group' were prescribed a 
mean of 3.5 each, SD 1.69, with a range from 1-7 medications. There were 12 participants 
(16%) who had no psychotropic medications. General health medications were prescribed to 71 
participants (97%). Seizure management medications comprised 30% percent of all 
psychotropic medications prescribed. 
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Almost 50% of the sample had been taking psychotropic medications from 1 to 5 years, 
and 42% for more than 6 years, see Table 2. No prescriptions were recorded to have been 
prescribed for longer than 10 years.-The use of psychotropic medication by different subgroups 
is depicted in Table 2. 
Table 2 
Subgroups Taking Psychotropic Medications as a Percentage of the Sample 
Psychotropic No 12sychotro12ic 
N (%) N (%) 
Participants 61 83.6 12 16.4 
Psychiatric 12 100 0 0.0 
Seizure Disorder 31 100 0 0.0 
Problem Behaviours 41 93.2 3 6.8 
Note. Some participants' belonged to more than one subgroup 
Table 3 
Duration of prescribed psychotropic medications within sample population, 






Yearly Medication Changes 












General health medications were found to increase over the 12-month period by 41 
prescriptions across the whole sample, see Figure 2 below. Prescribed psychotropic medications 
per person fluctuated very little over the one-year period, see Figure 3. The most changes across 
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the year took place within the anti-convulsant medication class. The total psychotropic 
prescriptions decreased by one prescription over the full year period. 
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Figure 2. Changes in the total number of prescribed medications across the sample from Feb 
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Figure 3. Changes in the mean number of all psychotropic medications per individual from Feb 
2009 to Feb 2010. Error bars represent standard errors. 
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Although there were few changes in the mean number of psychotropic medications per 
individual across the year, there were changes in dose (increase or decrease), and the start and 
stop of several medications for some individuals, see Figure 4. A total of 17 individuals had 
medication changes across the year period. These smaller scale changes were not evident when 
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Figure 4. Yearly changes in the number of prescribed psychotropic medications. 
Medication Classes 
Over the year, the average rate of different medication classes prescribed psychotropic 
medications across quarters were: antipsychotics, 18.4%; anti-anxiety, 26.2%; antidepressants, 
14.8%; anticonvulsants/mood stabilizers, 33.8%; hypnotics, 1.4%; stimulants, .5%; typical anti-
psychotics, 4.9% (see Figure 5). The most prevalent drug classes were anti-psychotics, anti-
convulsants, and anti-anxiety medications. 
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Figure 5. Number of psychotropic medications prescribed from different classes over the year 
period. 
Standard Daily Psychotropic Medications 
The three most prevalent daily (standard) psychotropic medications prescribed were: 
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Olanzapine, Risperidone, and Quetiapine as can be seen in Figure 6. The top three medications 
are all antipsychotics. The fourth most prevalence group of prescribed medications included: 
lorazepam, divalproex sodium, and citalopram. There were also several first-generation (typical) 
anti-psychotics still prescribed within this sample, they were: haloperidol, methotrimeprazine, 
and perphenazine. Methotrimeprazine was the 11 th most prevalent medication, despite being an 
older generation antipsychotic, with a large side effect profile. 
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Figure 6. Profile of prescribed standard daily psychotropic medications. Medications prescribed 
only for seizure control and PRN medications are not included in this table. 
PRN Medications 
Within this sample of 73 participants, 24 individuals, 33%, were prescribed 'Pro re nata' 
(PRN) psychotropic medications, meaning prescribed as needed. The most prevalent PRN 
medication prescribed was, Lorazepam (Ativan), see Figure 7. A total of 31 individuals, (42%), 
from the entire sample, were prescribed Lorazepam as a PRN medication. A total of 14 
individuals, 19%, were prescribed two or more psychotropic PRNs. The most prevalent 
combination of prescribed psychotropic PRN medications was Lorazepam and Quetiapine 
(Seroquel). See Table 4 for all Psychotropic PRN combinations. 
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Figure 7. Number of reported psychotropic medication prescriptions for PRN purposes. 
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The rationales and number of individuals who were actually administered (not just 
prescribed) PRNs, changed across the year, see Table 5. The most prevalent rational for PRN 
use was "anxiety", followed by a medical reason (e.g. pain), self-injurious behaviour, and 
physical aggression. 
Table 5 
Number of PRN administrations quarterly 
Quarterly PRN Administrations 
Feb-09 May-09 Aug-09 Nov-09 Feb-l0 Totals PRN Rationale (n = 26) (n = 22) (n = 17) (n = 15) (n = 16) 
Verbal Assault 6 0 0 3 1 10 
Physical Aggression 28 17 2 0 1 48 
Property Destruction 8 1 0 1 1 11 
Anxiety 9 20 36 32 42 139 
Medical Appointments 4 4 2 2 0 12 
Medical Reason 16 6 29 4 14 69 
Self-Injurious Behaviours 12 29 16 0 0 57 
Attempted Physical 4 0 0 0 6 10 Assault 
Sleep Issues 0 0 2 3 2 7 
Obsessive Behaviour 0 0 0 0 1 1 
Total 87 77 87 45 68 364 
The rationales for PRN administration were grouped according to behavioural 
topographies. Destructive behaviour included PRNs administered to address: physical 
aggression towards others, self-injurious behaviour, and attempted physical assault. PRNs for 
anxiety were administered to participants experiencing anxiety that was visible, physical, or 
emotional. Other rationales included: verbal assault, medical appointments, obsessive 
behaviours, and sleep issues. Across the year the number of PRNs given for destructive 
behaviours decreased, and PRNs given for anxiety increased across the year, see Figure 7. The 
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overall quarterly rates of administered PRNs, decreased by 24%, across the year mainly due to 






: -.-Destructive behaviour i 
ID j 
10 j 
o _L _____________ ___________________ ___________ _ 
Feb-09 May-09 Aug-09 
Months 
I ~ Anxiety i 
........ Other 
Nov-09 Feb-l 0 
Figure 8. Quarterly rates of psychotropic PRN use based on rationale. 
Rationales for Psychotropic Medications 
The reasons for which psychotropic medications were prescribed are presented in Table 6. 
The most prevalent reason was identified as seizure control (with or without seizure disorder 
diagnosis), followed by anxiety and mood stabilization. Almost 11 % of the medications were 
prescribed for problem behaviours, which included: aggression, agitation, behaviour unspecified, 
and self-injurious behaviour (see Table 6). 
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Table 6 
Rationales for psychotropic medications (February 2009) 
Rationale Percent (%) 
Seizure control 26.0 
Anxiety 21.6 
Mood stabilizer 17. 




Bi polar 2.0 
OeD 1.6 
Tremors 1.6 
Behaviour unspecified 1.2 
Sleep 1.2 
Self-injurious behaviour 1.2 
Psychiatric 0.8 
Schizophrenia 0.8 
Tourette's symptoms 0.4 
Note. Rationales are listed in order from most prevalent to least prevalent. 
Relationships between Participant Characteristics and Psychotropic Medication Use 
Pearson correlations were used to examine the relationships between the following 
variables: age; support level; number of problem behaviours; psychiatric diagnosis; behaviour 
plan; and number of prescribed psychotropic medications, see table 7. The primary relationships 
of interest, were variables that affected that number of psychotropic medications that were used 
for either behaviour control or mental health issues (not seizure control), therefore, medications 
prescribed for seizure control were excluded. Age showed a significant negative correlation with 
the number of problem behaviours. The number of problem behaviours was significantly 
correlated with the number of psychotropic medications and with the presence of a behaviour 
plan. 
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Notes: Psychotropic medications did not include medications for the purpose of seizure management 
** P < 0.01, two-tailed, * P < 0.05, two-tailed 
Adherence to Standards of Practice 
Canadian 'Consensus Guidelines for the Primary Care of Adults with Developmental 
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Disabilities' (Sullivan et aI., 2006) recommends that medications are reviewed regularly (ideally 
every three months) with regards to (indication, dosage, efficacy, compliance, side effects); that 
dates and changes be monitored by the same health care provider; serum levels where applicable 
are tested regularly; and that psychiatric or behavioural pharmacological medications are 
reviewed at a minimum yearly basis to ensure appropriate or justified use for long term 
interventions. The data indicate that only 12.3% of the participants on psychotropic medications 
had a documented scheduled medication review within three months of the start month of this 
study. Individuals review dates for the remainder of the year period were not provided in these 
data. The documented rationales for receiving psychotropic medications did not correspond with 
reported numbers of psychiatric diagnoses. Excluding seizure medications, the majority of 
psychotropic medications, 77%, were prescribed to individuals with no documented psychiatric 
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diagnosis while 20.8% were prescribed for diagnosed psychiatric disorders. The rationale was 
unknown for 3 to 8 psychotropic medication prescriptions in different quarters. Only 48% of the 
participants with identified problem behaviours and no psychiatric diagnoses had an adjunct 
formal behaviour intervention. 
Discussion 
This study was designed to examine the prevalence and rationales for psychotropic drug 
use in a sample of 73 adults with ID living in community residential settings across a one-year 
period. This study provides new and more detailed information about the rationales for 
psychotropic medication use, prescribing practices, usage of PRN medications over time, types 
of medications changes over time, and whether psychotropic medications were reviewed within 
three months of the start of this study. Although the longitudinal data revealed that there were 
few medications changes over the year period (i.e. dose, new medications, stopped medications), 
information on the duration of use of psychotropic medications revealed that most individuals 
had been receiving psychotropic medications on a long-term basis and still rates of problem 
behaviours were high. The overall prevalence of psychotropic medication use and the use of 
polypharmacy in this sample was higher than expected based on previous prevalence studies 
from North America and Europe (Aman, Sarphare, Burrow, 1995; Burd, et al., 1997; Holden & 
Gitlesen, 2004; Lott et aI., 2004; McGillivay & McCabe, 2006; Stolker et aI., 2002). The 
examination of individual characteristics and variables and their relationships with psychotropic 
medication use revealed several significant relationships. The number of problem behaviours 
was found to significantly relate to the number of prescribed psychotropic medications, and the 
presence of a behaviour plan. Age was found to negatively correlate with the number of problem 
behaviours. 
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Patterns of Usage 
Previous studies from North America and Europe showed that the prevalence of 
psychotropic medication use in people with ID ranged from 16% to 83% (Aman, Sarphare, 
Burrow, 1995; Burd et ai., 1997; De Kuijper et aI, 2010; Engelman et ai., 2004; Holden & 
Gitlesen, 2004; Lott, McGregor, McGillivay & McCabe, 2006; Stolker et ai., 2002; van 
Schrojenstein Lantman-de Valk et ai., 1995). This results of this study revealed that 84% of 
participants in our sample were receiving psychotropic medications. The rates of psychotropic 
polypharmacy (2 or more medications per person) in this sample were higher than expected in 
that nearly 75% of the participants were taking two or more psychotropic medications. Prior 
studies showed that individuals with polypharmacy ranged between 7-62 % (Lott et aI., 2004; 
McGillivay & McCabe, 2006). This present study found pervasive use of polypharmacy within 
this sample which is not consistent with emerging research and care guidelines warning against 
poly-prescribing of psychotropic medications for individuals with ID (Deb, et aI., 2006; Deb et 
aI., 2009; Kalachnik et aI., 1995; Sullivan et aI., 2006). The higher rates may have been related 
to the definition of polypharmacy used in this study. Studies on the prevalence of Epilepsy in 
individuals with ID have been found to range between 16-26% (McGrother, Baumik, Thorp, 
Hauk, 2006). Although only 14 individuals, 19%, had formally documented diagnosed seizure 
disorders in this sample, medications for seizure control were prescribed to 31 participants, 
(42%). This incongruence warrants further investigation. The number of prescribed seizure 
control medications was higher than expected. Additionally, more than half of the 31 individuals 
with seizures were prescribed two or more different psychotropic medications for seizure 
controi. The high rates of medications for seizure control in this sample should be closely 
monitored and evaluated as seizure management with medication is typically long-term. The 
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high rates of psychotropic medications used within this sample, in combination with the long-
term use of seizure medications, sets the stage for possible drug interactions, polypharmacy, and 
increases the likelihood of adverse side effects (Mahan et aI., 2010; Matson et aI., 2010). 
This present study, replicated previous findings about the most common classifications of 
prescribed psychotropic medications (Holden & Gitlesen, 2004; Lott et aI., 2004; Tsakanikos et 
aI., 2007). The results showed that the most frequently prescribed classes for either mental 
health issues or behaviour control were anti-anxiety medications, antipsychotics, and to a lesser 
degree antidepressant medications. The most prevalence psychotropic class prescribed, 
irrespective of rationale, was the anti-convulsant class. This finding was not expected as only 
slightly less than half of the sample was reported to have had seizures. This may however be 
reflective of the increasing use of anti-convusant medications for mood stabilization purposes 
(NIMB, 2008). The treatment of psychiatric disorders in individuals with ID using 
pharmacological interventions approved for the neurotypical mental health population is 
generally accepted (Deb, 2006). However, psychotropic drug use has stretched far beyond the 
treatment of psychiatric disorders in individuals with ID. An earlier Canadian study found that 
psychotropic medications were over-prescribed given the number of persons who had psychiatric 
diagnoses (Feldman, Atkinson, Foti-Gervais, & Condillac, 2004). Current results produced 
similar results and show that nearly 6 years later the number of people prescribed psychotropic 
medications still does not correspond with the number of diagnosed psychiatric disorders. 
The current results also highlight other areas of concern: a) polypharmacy, b) the 
extensive long term of use of psychotropic medications, and c) the lack of documented regular 
medication reviews with physicians. Most individuals in this sample had been receiving 
psychotropic medication over long-term periods and research has shown that individuals with ID 
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are at greater risk of developing side effects because of their underlying neurological differences 
and possible neurological damage from long-term exposure to these medications (Mahan, et aI., 
2010; Matson et aI., 2010). Despite this emerging information about the increased risk for 
adverse effects related to long term and polyprescribing of psychotropic medications, the 
prevalence of long-term use and polypharmacy is evident in this sample (Allen, 2008; Deb et aI., 
2009; Haw & Stubbs, 2005; Mahan et aI. , 2010; Matson et aI., 2010; Valdovinos et aI., 2005). 
Furthermore, literature has shown that some side effects can actually lead to the development or 
increase in behavioural issues like agitation, aggression, disinhibition, hostility, restlessness, and 
sleep disturbances (Allen, 2008). Research has also shown that some side effects are reversible 
with the discontinuation of a medication, whereas some effects are permanent, and others can be 
life threatening (e.g. neuroleptic malignant syndrome) (Advokat et aI, 2000). If side effects are 
not monitored more closely as a standard practice within this vulnerable population then 
psychotropic medications should not be used as commonly. What's more, general health 
medications are also often added to treat the side effects of psychotropic medications, thus 
increasing the number of prescribed medications and potential for drug interactions (Valdovinos, 
et al., 2005). The increase in prescribed general health medications during this study may be 
related to the management of emerging side effects from the long-term use of the psychotropic 
medications. 
Characteristics Related to Psychotropic Medication Use 
The variables related to psychotropic medication use were consistent with the existing body 
of literature. As was expected, there was a positive correlation between the number of problem 
behaviours and the number of prescribed psychotropic medications. Literature consistently 
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indicates that problem behaviours are predictors for the use of psychotropic medications in adults 
with ID (Aman, Sarphare & Burrows, 1995; de Kuijper et aI, 2010; Holden & Gitlesen, 2004; 
Singh, Ellis & Wechsler, 1997; Tsakanikos, et aI., 2007). More specifically, overt behaviours, 
such as, physical aggression, temper tantrums, pestering staff, self-injury, property destruction, 
verbal abuse, and over-activity, have been identified as risk factors for the use of psychotropic 
medications, despite the absence of any diagnosed psychiatric disorders (Tsakanikos et aI., 
2007). Studies across time and geographical regions have continued to find that problem 
behaviours are the rationales for that specific use of psychotropic medications, especially from 
the anti-psychotic classification (de Kuijper et aI., 2010; Holden & Gitlesen, 2004; Stolker et aI., 
2002). 
There was also a relationship identified between increasing age and a decrease in the number 
of problem behaviours. One possible explanation could be the decreased mobility and energy of 
individuals of older ages, resulting in a decrease in some overt problem behaviours. 
Furthermore, the changes in neurological functioning and extrapyramidal side effects resulting 
from long-term exposure to psychotropic medications may also affect an individual's mobility 
and ability to engage in overt problem behaviours. 
There was also a large discrepancy between the number of problem behaviours in the 
sample and the number of behaviour plans. This disparity may be partially explained by: a) 
variations in the severity of problem behaviours, where less severe behaviours may not prompt a 
referral to a behaviour support agency; b) behaviour plans may have been developed for 
individuals in the past, although they are no longer active; c) individuals may have been referred 
for behavioural supports and remain on a waiting list; d) support staff may be hesitant to make a 
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referral for behavioural support due to the response effort typically involved in the 
implementation of behaviour support plans. 
Standards of Practice 
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There have been several published guidelines regarding the best-practice 
recommendations for the use of psychotropic medications with people with ID (Deb et aI., 2006; 
Deb et aI., 2009; Sullivan et aI., 2006). Previous studies have revealed a widespread lack of 
commitment to following published guidelines on the use of psychotropic medications in 
community settings (Cheetham & Bradley, 2010; de Kuijper et aI., 2010; Holden & Gitlesen, 
2004; Marshall, 2007). Similarly, in this present study, less than a quarter of the participants 
who were taking psychotropic medications had a scheduled medication review within three 
months of the start of the study. It is disturbing that individuals taking an average of 3 to 4 
psychotropic medications each, were not scheduled a review at least every three months, since it 
is understood that individuals with ID are more susceptible to negative side effects, increasing 
with number of psychotropic medications prescribed (Mahan et aI., 2010). Furthermore, the 
rationales for prescribing the psychotropic medications did not correspond with actual numbers 
of psychiatric diagnoses, but corresponded more closely the presence and number of problem 
behaviours. Literature reports that agencies or caregivers will often turn to pharmacological 
interventions as the first line treatment for treating maladaptive or challenging behaviours 
(Matson, Mayville, Pinkston, et aI., 2000). 
Guidelines from Canada and Europe have made recommendations that psychotropic 
medications not be used for convenience; in excess; or as a substitute for other psychological 
services or if they appear to interfere with quality of life (Deb, Kwok, Bertelli, Salvador-Carula, 
PSYCHOTROPIC MEDICA nONS AND ID 48 
et aI., 2009). Guidelines suggest that frequent drug changes, poly prescribing, high doses of 
medication, and the long-term use of benzodiazepines and anti-cholinergic medications be 
avoided (Deb, 2006; Deb, Kwok, Bertelli, Salvador-Carula, et aI., 2009; Sullivan et aI., 2006). 
This study demonstrates that further efforts are necessary to increase the implementation of the 
Standards of Practice and Health Care Guidelines in clinical practice. 
Multidisciplinary Approach 
Individuals with ID and mental health or behavioral issues have complex need and thus 
would benefit from a multidisciplinary and multimodal approach to the assessment and treatment 
of behavioural or mental health issues (Davis, Barnhill, Saeed, 2008). Literature indicates that 
treatment success can be improved through collaboration between medical and 
psychological/behavioural professionals, self-advocates, parents, and support staff (Dosen, 
2007). Collaboration between professional would support current guidelines that clearly 
recommend a thorough assessment of biological, developmental, psychological, social, and 
environmental influences be conducted prior to the use of a pharmacological intervention for 
challenging or problem behaviour (Dosen, 2007). Furthermore, the implementation demands of 
various intervention techniques should also be considered in relation to an individual's support 
network and their ability to effectively provide or support the most appropriate treatments 
(Fisher, Cea, Davidson, Adam, 2006). 
It has also been recommended that the treatment planning process be recognized as a 
combined effort, whereas "the professionals carry the responsibility to communicate the plan 
using accessible format to the person with learning disabilities and their carers, the carers and 
patients have an equal responsibility to pass the right information to the professionals in the right 
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way" (Deb, Sohanpal, Soni, Lenotre, 2007). Wachtel & Hagopian (2006) proposed a 
'neurobehavioral model' towards assessment and treatment, which incorporates medical/ 
psychiatric and operant components in assessment, diagnosis, and treatment. Again the 
application of this model would require the collaborative efforts of medical professionals and 
psychologist or behaviour analysts in conducting accurate assessments and developing the best 
possible treatments based on assessment results. 
A multidisciplinary approach would help ensure that treatment strategies would address 
any biomedical symptoms, aim to enhance quality of life for the individual with ID and their 
caregivers, and focus on long-term positive changes (Deb, 2006). Furthermore, objective criteria 
to indicate changes during an intervention should be clearly defined and then used to evaluate 
treatment efficacy during any pharmacological intervention (Dosen, 2007). Basing treatments on 
empirical evidence will help ensure the best possible outcome for an individual, reduce potential 
for ethical misconduct within this population, and hopefully prevent ongoing use of strategies 
that are causing a worsening of the problem or negative side effects. 
Study Strengths 
The present study had several strengths. This study examined a complex set of variables 
and their involvement with the use of psychotropic medication over a full year. Although 
previous studies have examined: prevalence, rationales, medication changes over time, predictors 
for psychotropic medication use, no single study has combined and reported on all these 
variables together (Aman, Sarphare, Burrow, 1995; Burd et aI., 1997; De Kuijper et aI, 2010; 
Engelman et aI., 2004; Holden & Gitlesen, 2004; Lott, McGregor, McGillivay & McCabe, 2006; 
Singh, Ellis & Wechsler, 1997; Stolker et aI., 2002; van Schrojenstein Lantman-de Valk et aI., 
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1995). This study was the first Ontario-based study to comprehensively examine the prevalence 
and patterns of psychotropic medication use in adults with ID living in community residential 
settings. The database that was used for this study provided consistent information about 
individuals across time. 
Study Limitations 
The present study had several limitations. One limitation is that this study had a limited 
sample size of 73 individuals who were all supported by the same agency. Another limitation is 
that the investigator did not have access to diagnostic reports to confirm what was inputted into 
the database. Third, due to the aging population sample, there may have also been some missing 
diagnostic information due to the lack of genetic tools or stringent diagnostic criteria when 
individuals were initially diagnosed as children. Although the 'level of support' ratings reported 
for individuals in this sample were related to 'level of functioning' or 'severity of ID', there were 
no IQ scores or standardized assessment results available for participants. With regard to the 
recorded rationales for different medications, it is believed that some behavioural issues may 
have been described in psychiatric terms, such as, 'agitation' being reported as 'anxiety' as the 
reason prescribed. There was also no information about prescribing physicians' expertise or 
specialty (i.e. psychiatry or family physician). 
Data checks were completed on the drug categorizing by using the excel sort function to 
review specific drugs and their corresponding drug classifications before analyses were started. 
All data were taken from one master excel spreadsheet and totals or queries were cross-checked 
between excel and PASW. Totals were primarily calculated using descriptive statistics in 
PASW, a few using column totals calculated in excel. Although there may possibly be a small 
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margin of human error, it is unlikely that this margin would dramatically impact any of the 
results given the large number of medications in this sample. 
Future Research 
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Future studies should examine the accuracy and variation of psychiatric diagnostic 
methodologies used with the population of individuals with II) currently living in community 
residential settings, to evaluate the current practices taking place. More thorough 
biopsychosocial assessments would be expected to assist in treatment planning and to ensure 
appropriate use of psychotropic medications for behaviour management purposes. It is important 
that future research also compare larger samples across different regions in Ontario and Canada 
to identify any differences in prescribing practices from urban and rural locations, as well as, the 
most common types of drugs prescribed by family practitioners vs. psychiatrists' vs. Emergency 
physicians. Future studies should carefully examine the main outcome effects and any side 
effects of psychopharmacological interventions for problem behaviours and psychiatric disorders 
in individuals with ID living in the community (Matson et aI., 2000, Deb, 2007). There is also 
more research is needed which examines existing obstacles to the utilization of behavioral 
services. The methodological rigor of efficacy studies examining different medications for 
behaviour management purposes can be improved by: completing both functional assessments of 
behaviour and appropriate psychiatric assessments prior to treatment implementation; conducting 
randomized control trials; accurately monitoring and reporting adverse side effects; increasing 
the length of treatment or study periods; including longer follow ups; and providing objective 
measures to monitor (psychopharmacological or behavioural) treatment outcomes and side 
effects (Matson & Neal, 2009; Tyrer et aI., 2008). 
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Because individuals with ID have been identified as more vulnerable to the adverse side 
effects of long-term use of psychotropic medications (Mahan et aI., 2010; Matson, Fotstad, Neal, 
Dempsey et aI., 2010), they would benefit from studies that investigated options about how to 
decrease the long-term use or misuse of psychotropic medications. Use of the 'Consensus 
guidelines for primary health care of adults with developmental disabilities' (CME, 2006) or the 
new Ontario quality assurance measures as explained in the 'Services and Supports to Promote 
Social Inclusion of Persons with Developmental Disabilities Act 2008' , could be implemented as 
a medication reduction intervention. The existing barriers to the implementation of these 
guidelines could also be further investigated. Data from this present study could be used as the 
baseline, and future data as the changes measure. Research should also investigate the benefits 
or challenges in using a multidisciplinary biopsychosocial or neurobehavioural approach in 
treatment selection for individuals with ID (Griffiths, & Gardner, 2002; Wachtel & Hagopian, 
2006). The biopsychosocial and neurobehavioural models would include biomedical 
assessments (including psychiatric assessment if needed) and functional assessments of 
behaviour prior to any medication and/or behavior plan administration and to account for any 
behavioural, social, or biological factors, which might contribute to problem behaviours or 
psychiatric illness (Deb et aI., 2007; Griffiths, & Gardner, 2002; Wachtel & Hagopian, 2006). 
Conclusions 
Ideally, the use of psychotropic medications with individuals with ID for mental health 
issues or behaviour control would be based on the results of a thorough biopsychosocial 
assessment and empirical evidence of the proposed treatment efficacy. Some researchers suggest 
that the prevalent use of psychotropic medications is related to a reactive first-line response to 
PSYCHOTROPIC MEDICATIONS AND ID 53 
manage crises, (La Malfa, et aI., 2006; Matson, 2007; Matson et aI., 2000; Matson et aI., 2000; 
Santosh, & Baird, 1999; Tsakanikos, Costello, Holt, et aI., 2007). The use of psychotropic PRNs 
is also considered a relatively acceptable method of crisis intervention. There may also be 
increased reliance on PRN medication as some jurisdictions, including Ontario, limit or prohibit 
the use of physical restraint and other intrusive behavioural procedures (Jacobson, Foxx, Mulick, 
2005). Nonetheless, as described throughout this paper, the efficacy claims of studies examining 
various pharmacological interventions for the purposes of behaviour management for persons 
with ID must be interpreted with caution and with an awareness of the existing methodological 
issues (Matson & Neal, 2009; Tyrer et aI., 2008). Psychotropic medications for behaviour 
management purposes for individuals with ID should only be used when deemed appropriate 
following a thorough biopsychosocial assessment of the individual and possible causes of 
problem behaviours, and should be followed by the prescribing physician to ensure ongoing 
careful monitoring and rationale for any long-term uses. 
Hopefully, over time there will be an increased willingness of the medical, psychological, 
and behavioural communities to collaborate in the treatment planning for mental health issues 
and behaviour problems in individuals with ID. This collaboration can be realized through 
dissemination of ongoing research in medical, behavioural, and psychological fields, increased 
public awareness about disability issues, and growing political pressures to provide lifelong 
ethical and effective treatment programs for individuals with ID. The integration of literature 
from medical, behavioral, and psychological research is essential in order to promote 
collaboration, rather than divergence in, treatment provision and future research directions. The 
regular dissemination of knowledge will help break down some of the existing barriers, such as, 
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a lack of discourse or communication across professions, to better enable most effective clinical 
practices and ethical treatment of individuals with ID living in the community. 
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Appendix A 
Medication Class Main Neurological Effects Reasons for Administration 
Antipsychotics: 
Typical: 
Haloperidol,_ Thioridazine, Potent dopamine 2 receptor Psychiatric: schizophrenia, psychotic 
chlorpromazine, perphenazine antagonism depression, mania, dementia 
Dopamine (D2) receptor 
Atypical: antagonism 
Risperidone (Risperidal) Behavioural: aggression, property 
Clozapine (Clozaril) Potent D2 receptor and 5HT destruction, agitation 
Quetiapine (Seroquel) antagonism (Deb et aI., 2008; Kern, 1999) 
Olanzapine (Zyprexa) D 1,2,3,4 antagonism 
Antidepressants 
Selective Serotonin Reuptake 
Inhibitors (SSRI): F1uoxetine, Potent 5HT reuptake inhibition Psychiatric: Depression, panic disorder, 
Fluvoxamine, Sertraline, 5HT agonism, weak D2 reuptake obsessive-compulsive disorder, eating 
Paroxetine, Citalopram inhibition disorders and sleep disturbances. 
5ht agonist: Buspirone 5HT agonism Behavioural: self-injury, aggression, sleep 
Tricyclic antidepressants~ 5HT reuptake inhibition, potent problems 
Clomipramine, imipramine, muscarinic2, histaminergic 1 , (Deb et aI., 2008; Kern, 1999) 
Desipramine, amytryptyline adrenergic2 antagonism 
Mood Stabilizers & Antiepileptics 
Psychiatric: bipolar disorder 
LithiumCarbamazepine Inhibition of inositol-I-phosphatase 
Valproate enzymeDecreases y aminobutyric Behavioural: aggression, sleep 
Divaloprex acid (GAB A) activity disturbances, agitation, irritability, self-
Decreases GABA catabolism injury, increased vocalizations, decreased 
attention span 
(Deb et aI., 2008; Kern, 1999) 
Stimulants 
Methyphenidate Releases dopamine and inhibits Psychiatric: attention deficit hyperactivity 
Dexedrine reuptake disorder (Deb, 2006) 
Anxiolytics 
Benzodiazepines {BDZ} Increases GABA activity through Psychiatric: anxiety disorders, panic 
Diazepam, lorazepam, c10nazepam agonism of BDZ receptor disorder post-traumatic stress disorder 
Other: Buspirone Enhances 5-HT activity 
Behavioural: aggression, self-injury 
Other 
Opioid Antagonists Blocks opioid receptors Behavioural: self-injury 
Naltrexone (Kern, 1999) 
